As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to [Benzinga Pro.
Here's the latest list of major overbought players in this sector.
Exact Sciences Corp (NASDAQ: EXAS)
- On Nov. 20, Abbott Laboratories (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion. The buyout marked the biggest deal of the year in the global health-care sector. The company's stock gained around 51% over the past month and has a 52-week high of $101.87.
- RSI Value: 89.8
- EXAS Price Action: Shares of Exact Sciences fell 0.1% to close at $101.20 on Monday.
- Edge Stock Ratings: 91.33 Momentum score.
Haemonetics Corp (NYSE: HAE)
- On Nov. 6, Haemonetics posted upbeat second-quarter earnings and raised FY2026 EPS guidance. Haemonetics reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.11 per share. The company reported quarterly sales of $327.316 million which beat the analyst consensus estimate of $311.399 million. The company's stock gained around 61% over the past month and has a 52-week high of $88.31.
- RSI Value: 89.4
- HAE Price Action: Shares of Haemonetics fell 0.5% to close at $80.96 on Monday.
As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to [Benzinga Pro.
Here's the latest list of major overbought players in this sector.
### Exact Sciences Corp (NASDAQ: EXAS)
- On Nov. 20, **Abbott Laboratories** (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion. The buyout marked the biggest deal of the year in the global health-care sector. The company's stock gained around 51% over the past month and has a 52-week high of $101.87.
- **RSI Value:** 89.8
- **EXAS Price Action:** Shares of Exact Sciences fell 0.1% to close at $101.20 on Monday.
- Edge Stock Ratings: 91.33 Momentum score.
### Haemonetics Corp (NYSE: HAE)
- On Nov. 6, Haemonetics posted upbeat second-quarter earnings and raised FY2026 EPS guidance. Haemonetics reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.11 per share. The company reported quarterly sales of $327.316 million which beat the analyst consensus estimate of $311.399 million. The company's stock gained around 61% over the past month and has a 52-week high of $88.31.
- **RSI Value:** 89.4
- **HAE Price Action:** Shares of Haemonetics fell 0.5% to close at $80.96 on Monday.
<p>As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. </p>
<p>Here's the latest list of major overbought players in this sector.</p>
<h3 class="wp-block-heading"><strong>Exact Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EXAS">EXAS</a>)</strong></h3>
<ul class="wp-block-list">
<li>On Nov. 20, <strong>Abbott Laboratories</strong> <a class="ticker-link" data-ticker="ABT" data-exchange="NYSE" href="https://www.benzinga.com/quote/ABT" target="_blank" rel="noopener">(NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ABT">ABT</a>)</a> agreed on Thursday to acquire cancer screening company Exact Sciences for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion. The buyout marked the biggest deal of the year in the global health-care sector. The company's stock gained around 51% over the past month and has a 52-week high of $101.87.</li>
<li><strong>RSI Value:</strong> 89.8 </li>
<li><strong>EXAS Price Action:</strong> Shares of Exact Sciences fell 0.1% to close at $101.20 on Monday.</li>
<li>Edge Stock Ratings: 91.33 Momentum score.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/exas"><img loading="lazy" decoding="async" width="887" height="187" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/01202144/image-27.png" alt="" class="wp-image-1191832" style="width:598px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/01202144/image-27.png 887w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/01202144/image-27-300x63.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/01202144/image-27-768x162.png 768w" sizes="(max-width: 887px) 100vw, 887px" /></a></figure>
<h3 class="wp-block-heading"><strong>Haemonetics Corp <a class="ticker-link" data-ticker="HAE" data-exchange="NYSE" href="https://www.benzinga.com/quote/HAE" target="_blank" rel="noopener">(NYSE:<a class="ticker" href="https://www.benzinga.com/quote/HAE">HAE</a>)</a></strong></h3>
<ul class="wp-block-list">
<li>On Nov. 6, Haemonetics posted upbeat second-quarter earnings and raised FY2026 EPS guidance. Haemonetics reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.11 per share. The company reported quarterly sales of $327.316 million which beat the analyst consensus estimate of $311.399 million. The company's stock gained around 61% over the past month and <a href="https://www.benzinga.com/quote/HAE">has a 52-week high</a> of $88.31.</li>
<li><strong>RSI Value:</strong> 89.4</li>
<li><strong>HAE Price Action:</strong> Shares of Haemonetics fell 0.5% to close at $80.96 on Monday.</li>
</ul>
<p>BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.</p>
<p><strong>Read This Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/12/49134333/top-2-financial-stocks-that-may-collapse-this-quarter-3">Top 2 Financial Stocks That May Collapse This Quarter</a></strong></li>
</ul>
<p>Photo via Shutterstock</p>